Close Menu
Home › Interpace Dx Q1 Revenues Climb 37 Percent

Interpace Dx Q1 Revenues Climb 37 Percent

May 15, 2018
|
staff reporter

NEW YORK (360Dx) – Interpace Diagnostics today reported a 37 percent hike in its first quarter revenues.

For the three months ended March 31, Interpace posted $4.8 million in revenues, up from $3.5 million in the year-ago quarter, and beat the consensus Wall Street estimate of $4.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
25
Featured Webinar

Cell-free DNA Testing for Fetal Aneuploidy: Lessons Learned and Implications for Clinical Practice

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
31
Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

What's Popular?

In Molecular Diagnostics

  1. Cowen, William Blair, JP Morgan Initiate Coverage of Adaptive Biotechnologies

  2. Myriad Genetics Settles Improper Medicare Billing Complaint for $9.1M

  3. HiberGene Outlines Plans for Low-Cost Point-of-Care Molecular Diagnostic System

    Premium

  4. Roche Expands Global Access Program to Include Tuberculosis, Hepatitis, HPV Tests

  5. Interpace Diagnostics, SelectHealth Sign Coverage Agreement for Thyroid Cancer Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.